| Literature DB >> 10622573 |
V Soriano1, J Garcìa-Samaniego, R Rodrìguez-Rosado, J Gonzàlez, J Pedreira.
Abstract
As deaths from AIDS continue to decline in HIV-infected persons, liver disease is becoming an increasing cause of hospital admission and death in HIV-HCV co-infected persons. The problem is particularly relevant among intravenous drug users and haemophiliacs, most of whom are co-infected. Moreover, the risk of hepatotoxicity is higher with anti-HIV drugs among patients with chronic hepatitis C. Treatment with alpha-interferon provides a similar rate of response in non-severely immunosuppressed HIV-positive subjects as in HIV-negatives, and preliminary results from trials using the combination of interferon plus ribavirin in HIV-HCV co-infection look very promising for both rates of sustained response and safety.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10622573 DOI: 10.1016/s0168-8278(99)80387-0
Source DB: PubMed Journal: J Hepatol ISSN: 0168-8278 Impact factor: 25.083